DSIP (Delta Sleep-Inducing Peptide)
Emideltide; DSIP; WAGGDASGE nonapeptide; Deltaran (Russian formulation)
The Ground Truth Score
four plain questions, never one numberOld peptide, thin and contradictory human data
Bottom line
DSIP has a 50-year research history and a handful of small human sleep trials, but the effects were weak, inconsistent, and never replicated at modern trial standards, so it remains an unresolved curiosity rather than a proven sleep aid.
Does the science back it?
Do real people feel it?
Is it safe?
Could it be placebo?
Can you legally get it?
Advisory: noRecommendation declinedThe same advisory committee that recommended six other peptides declined this one. Given how permissive that committee was, a no from it carries weight.
The only one of the seven the committee declined, on July 24 2026. Cited evidence: a single narcolepsy case report and two small uncontrolled opioid-withdrawal studies, with human data collected by IV for a product proposed as a subcutaneous injection.
Legal status as of 2026-07-24. This is a separate axis from the grades above, and it does not move them. A vote about who may legally prepare a compound is not evidence that the compound works.
"Do real people feel it?" is anecdote, not proof, weighted up because the science is thin, never because it beats a trial. And "could it be placebo?" is not an insult: if you feel better, that's real to you. The point is only to know whether you're paying peptide prices for an expectation.
Why is the evidence this thin? It's mostly economics →
Dose at a glance
full dosing ↓Reported (not prescribed) protocols: typically 100-250 mcg subcutaneously once nightly.
Reported, not prescribed. Verify your vial and your math.
First documented human use
First documented human use was in the early 1980s: small double-blind crossover and parallel-group studies (Schneider-Helmert and colleagues, ~1981-1984) gave synthetic DSIP by slow IV infusion at 25 nmol/kg to healthy volunteers and chronic insomniacs. These were genuine human trials, but small (6-16 subjects each, ~107 total across the program) and produced weak, partly placebo-confounded results. No modern, adequately powered, registered RCT of DSIP for sleep has been completed; no DSIP product is FDA-approved.
The pitch
What people claim it does
Stated plainly and neutrally, exactly as you'll hear it. We grade each one below.
- A naturally occurring 9-amino-acid brain peptide (isolated from sleeping rabbit blood in the 1970s) that is theorized to deepen slow-wave (delta) sleep.
- Promoted as a sleep 'modulator' rather than a sedative, with claims of no morning grogginess and of being more active when sleep is disrupted.
- Marketed for falling asleep faster, deeper sleep, lower nighttime cortisol/stress, and secondarily for pain and opioid/alcohol withdrawal.
- Has a long (50-year) literature and was described in a 2001 anesthesiology editorial as 'incredibly safe' in animal work.
- Now under formal FDA Pharmacy Compounding Advisory Committee (PCAC) review (scheduled July 24, 2026), which vendors frame as moving it 'closer to legal compounding.'
The data behind each bullet
What actually backs it
DSIP is a natural nonapeptide (sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) first isolated in the 1970s by Schoenenberger and Monnier from cerebral venous blood of rabbits in induced sleep.
Well-established and uncontested fact of biochemistry/history, documented across reviews and reference sources.
PubMed: DSIP review (Graf & Kastin) ↗Small human IV studies in the 1980s found modest improvements in sleep latency, sleep efficiency and slow-wave sleep, but effects were weak and partly attributable to placebo-group changes.
Several small double-blind human trials exist (single-dose and repeated dosing, healthy volunteers and chronic insomniacs), but they were small, used IV dosing, and reported weak/inconsistent benefit; authors themselves doubted major therapeutic value.
PubMed: DSIP human sleep / insomnia trials ↗After ~50 years no DSIP gene, precursor, or specific receptor has been identified, and the link between DSIP and sleep has never been definitively characterized.
This is the central conclusion of the 2006 review explicitly titled 'DSIP: a still unresolved riddle.'
PubMed: DSIP a still unresolved riddle (2006) ↗Reported benefits beyond sleep (analgesia, stress-limiting/neuroprotective, antioxidant, anti-tumor, anticonvulsant, opioid/alcohol withdrawal) rest mainly on animal and in-vitro work.
These claims derive overwhelmingly from rodent and cell studies plus a small number of older Eastern-European clinical reports; they are not established by Western controlled human trials.
PubMed: DSIP analgesia / stress / oncostatic studies ↗DSIP (Emideltide) is not FDA-approved and is under active regulatory review; it was on the FDA 503A Category 2 bulk-substance list and is scheduled for PCAC review on July 24, 2026.
Confirmed by FDA 503A bulk drug substance rulemaking and the published PCAC meeting agenda; secondary reporting notes April 2026 changes to its category status.
ClinicalTrials.gov / FDA: search Emideltide DSIP ↗Prove it
Can you tell if it's working?
The honest test: if it's working, is there any objective way to see it — a blood marker, a scan, a wearable? For a lot of peptides the answer is no, and that's worth knowing before you spend on labs or gear.
The only honest objective tracker is a sleep wearable (Oura/WHOOP) run as a blinded on/off n-of-1 — and even then the human signal is weak, largely unreplicated, and placebo-prone.
Bloodwork
Nothing on a routine panel confirms this one. Anyone who says otherwise is guessing.
DSIP is an endogenous nonapeptide that acts centrally to modulate sleep architecture and the stress/HPA response. It has a very short plasma half-life, is not itself an analyte on any routine panel, and controlled human infusion studies show it does not reliably shift cortisol, ACTH, or other pituitary hormones — so it leaves no measurable fingerprint on standard bloodwork.
Read this before you spend on labs
Routine bloodwork cannot confirm DSIP is working. Its effect is on sleep and subjective calm/stress — a central-nervous-system, experiential endpoint that is captured only by a sleep study (polysomnography), wearable/actigraphy sleep metrics, or a validated sleep questionnaire, not by any LabCorp/Quest panel. The one plausible endocrine proxy people reach for — cortisol/ACTH — was specifically tested: controlled human DSIP infusion studies found no reliable effect on the HPA axis, so there is no hormonal backdoor either. Track efficacy with a sleep diary or wearable sleep-stage data, not labs. (Note: DSIP-immunoreactivity assays exist but are research-only and would only show the peptide is present, not that it is working.)
Other ways to track it
Oura/WHOOP (or Apple Watch) — sleep-onset latency, sleep efficiency, deep-sleep (slow-wave) minutes, nocturnal HRV, resting HR
If DSIP does anything in you, the plausible wearable signals are shorter sleep-onset latency and higher sleep efficiency versus your own baseline, possibly with higher nocturnal HRV and lower resting HR on nights it 'works.' Do NOT expect a reliable deep-sleep change: the human PSG trials were equivocal-to-negative on slow-wave/delta sleep despite the peptide's name, and consumer wearables stage deep sleep poorly, so that specific metric is the least trustworthy readout. Treat any single-arm improvement as likely placebo or regression to the mean until a blinded on/off design separates it.
Sleep is the ONLY domain DSIP has ever been studied for in humans, and small 1970s-80s IV-infusion polysomnography trials are the entire evidence base. They were mixed: some reported shorter latency and better efficiency versus placebo, but effects on slow-wave (delta) sleep — the peptide's namesake target — largely failed to replicate. A consumer wearable's latency/efficiency/HRV/resting-HR metrics are the closest accessible proxy, though only an approximation of lab EEG. Flip side: controlled human infusion studies found no consistent cortisol or ACTH change, so stress-hormone (urine/blood) assays are NOT a valid readout here — sleep and autonomic metrics are the only defensible target.
Bottom line
DSIP has no validated blood marker, and its only human-studied action is on sleep — shown only in small, mixed, unreplicated 1970s-80s IV-infusion PSG studies whose effect on slow-wave (delta) sleep, the peptide's own namesake, largely failed to replicate. A consumer wearable (Oura/WHOOP) can track the right category of things — onset latency, sleep efficiency, deep-sleep minutes, nocturnal HRV, resting HR — but only as an imperfect proxy for lab EEG, and deep-sleep staging specifically is the least reliable wearable metric. The felt endpoints (falling asleep faster, feeling rested) are highly suggestible, so the honest verdict is partial: run blinded alternating on/off blocks and never trust a single before/after. Urine or blood cortisol/ACTH is NOT a valid readout, since controlled studies showed no consistent HPA-axis effect.
Logging baseline vs retest is the whole game. The Truth Tracker is our free log for bloodwork, DEXA, genetics, and wearable data — bring your own numbers.
How to track it →Mechanism
How it's assumed to work
Assumed and still unproven. DSIP is amphiphilic and is hypothesized to modulate central sleep-regulating circuits, possibly via NMDA-receptor interaction and effects on neurotransmitter/neuroendocrine systems (lowering ACTH/cortisol, influencing GH/LH/somatostatin in animal data), rather than acting as a direct sedative. No specific DSIP receptor, gene, or precursor has ever been identified, so the mechanism remains theoretical. The persistence of next-day effects despite rapid blood clearance is taken to imply downstream/second-messenger action.
Dosing & handling
What users and clinicians report
Reported (not prescribed) protocols: typically 100-250 mcg subcutaneously once nightly. Common pattern is to start at ~50-100 mcg, titrate to 200-300 mcg by response; some use a 'pulse' of ~100-200 mcg nightly for ~10 days then a break. Note this diverges sharply from the original human trials, which used IV infusion at 25 nmol/kg.
These microgram subcutaneous doses come from forums, vendor charts and case-report-style observations, NOT from controlled trials, the trials that showed any effect used intravenous administration. Dose, route, and even whether the product is genuine DSIP are unverified for gray-market material. Higher doses (>500 mcg) are anecdotally linked to vivid/disruptive dreams and grogginess.
Timing & food
Most reported protocols inject 30-60 minutes (some say 1-2 hours) before bed. Interestingly, the original human data suggested a dose given earlier in the day could still improve the following night's sleep, implying a delayed/'modulatory' action rather than acute sedation. Typically dosed without regard to food; no strong fasted-vs-fed rationale exists since it is injected, not oral. Bedtime timing is mainly to align any subjective drowsiness with sleep onset.
Half-life
Very short. In-vitro and plasma estimates cluster around ~7-15 minutes (aminopeptidase degradation), with some sources citing up to ~30 minutes after subcutaneous injection. Notably, reported pharmacodynamic effects on sleep/stress are said to persist 6-8 hours, far outlasting the peptide's measured time in blood, a disconnect that is itself part of the 'riddle.'
Reconstitution sensitivity
Sold as a lyophilized (freeze-dried) powder reconstituted with bacteriostatic water and gently swirled (not shaken) to avoid degrading the peptide. As a small unmodified peptide it is considered fragile: keep lyophilized powder cold, store reconstituted solution refrigerated at ~2-8 C (39 F), minimize light and heat exposure, and use within a few weeks. Freeze-thaw cycling and rough handling should be avoided.
Real-world signal
What people actually report
Anecdote, not proof, weighted because the science is thin. Here's the record, graded on volume, consistency, and how credible the sources are.
Volume
Moderate. DSIP is a fairly well-known 'sleep peptide' in biohacker/peptide communities with steady forum discussion and many vendor writeups, but it is a niche relative to mainstream sleep aids, and a large share of available content is commercial rather than independent user reports.
Consistency
Low/inconsistent. The recurring community verdict is that DSIP is 'hit or miss': some report genuinely deeper sleep without grogginess, many report little or nothing, and a subset report vivid dreams or next-morning grogginess (often dose/timing dependent). This mirrors the mixed clinical literature.
Source credibility
Low-to-moderate. Much of the favorable signal originates from vendors and affiliate sites selling DSIP, which were down-weighted. Independent user reports exist but are subjective, uncontrolled, and frequently confounded by stacked compounds, so they constitute anecdote rather than evidence.
- Commonly reported (anecdote): deeper, more 'solid' sleep and feeling more rested, with users emphasizing the absence of the hangover/grogginess they get from antihistamines or prescription hypnotics.
- Just as commonly reported: 'it did nothing', a large share of users feel no clear effect, which is why the community broadly calls DSIP hit-or-miss and very individual.
- Vivid or intense dreams are a frequent theme, described as interesting by some and sleep-disrupting by others, and more likely at higher doses (anecdotally >500 mcg).
- A minority report mild next-morning grogginess, headache, or a 'heavy' feeling, usually attributed to dosing too high or too late and often resolved by lowering the dose or dosing earlier.
Placebo risk, High
Placebo risk is High because the primary endpoints (feeling rested, falling asleep faster, sleep 'quality') are largely subjective and highly suggestible, the gold-standard human trials themselves showed weak effects partly explained by placebo-group changes, and most real-world use is unblinded and stacked with other sleep interventions. Objective EEG slow-wave findings exist historically but were inconsistent and not reproduced in modern controlled conditions.
Risk panel
What could go wrong
Adverse events
In the small human studies and the largest tolerability data (~107 volunteers) DSIP was generally well-tolerated; the only reported acute effects were transient headache, nausea/GI upset, dizziness/vertigo, and occasional injection-site redness or soreness. No deaths or serious events were documented in that early literature.
Theoretical concerns
As an injectable peptide of gray-market origin, the FDA's stated concern is immunogenicity, the immune system reacting to the peptide or to manufacturing impurities, a class-level concern for compounded peptides rather than a DSIP-specific finding. Because DSIP touches stress-hormone (cortisol/ACTH), LH, GH and somatostatin pathways in animal data, theoretical endocrine perturbation cannot be excluded, though it has not been demonstrated as a clinical problem.
Contraindications
No formal contraindication list exists because DSIP is unapproved. Prudent caution applies to pregnancy/breastfeeding (untested; DSIP-like material occurs in human breast milk), and to anyone on sedatives, sleep medications, or with unstable psychiatric or endocrine conditions, given the lack of interaction data and the hormone-modulating signals seen in animals.
Honest unknowns
The biggest unknowns are long-term safety (no chronic-use human data at all), product identity/purity from research-chemical suppliers, true effective dose and route (historic studies used IV, not the subcutaneous dosing sold today), and whether any subjective benefit exceeds placebo. With no identified receptor or gene, even the basic biology is unsettled.
Confound watch
Users almost never run DSIP alone for sleep: it is frequently stacked with melatonin, magnesium, glycine, GHK-Cu, GH-secretagogues (CJC-1295/ipamorelin), or taken alongside improved sleep hygiene and reduced alcohol/caffeine, any of which can drive the perceived improvement. Concurrent GH-peptides especially confound 'deeper sleep' claims.
History
Discovery → first use → status
Update: the FDA advisory panel voted this one DOWN on July 24, 2026
Of the seven peptides reviewed at the July 23-24, 2026 PCAC meeting, this was the only one the committee declined to recommend for the 503A Bulks List, and the committee recommended the other six over its own agency's objections, so a no here is a meaningful signal. The stated reason was unusually weak evidence: a single patient case report for narcolepsy and two small uncontrolled studies for opioid withdrawal, with the additional problem that the human studies used an intravenous route while the proposal was for subcutaneous injection. That last point generalizes, so it is worth sitting with: evidence collected by one route does not automatically carry to another.
Vote recorded July 23-24, 2026; verified against FDA's meeting materials and contemporaneous reporting. Nothing here is final — check the current rule before acting.
FDA — PCAC meeting, July 23-24 2026 ↗- 1974-1977Schoenenberger and Monnier (University of Basel) isolate DSIP from cerebral venous blood of rabbits put into electrically-induced sleep; sequence determined as the nonapeptide WAGGDASGE.
- 1981-1984First human trials: small double-blind IV studies (25 nmol/kg) in healthy volunteers and chronic insomniacs report modest, inconsistent sleep improvements; ~107 subjects across the program.
- 1992Double-blind study in chronic insomniacs (PMID 1299794) finds only weak effects on sleep efficiency/latency, partly confounded by placebo-group change.
- 2001European Journal of Anaesthesiology editorial (Pollard & Pomfrett) calls DSIP 'incredibly safe,' noting no lethal animal dose and only transient headache/nausea/vertigo in humans.
- 2006Review titled 'DSIP: a still unresolved riddle' concludes the peptide's gene, receptor and sleep mechanism remain unidentified after three decades.
- 2020sDSIP becomes a popular gray-market 'sleep peptide' sold as lyophilized powder for self-administered subcutaneous injection (and nasal sprays), despite no modern efficacy trials.
- April 2026FDA 503A rulemaking updates the status of Emideltide (DSIP); reporting indicates removal from Category 2 pending advisory review.
- July 24, 2026DSIP/Emideltide scheduled for FDA Pharmacy Compounding Advisory Committee (PCAC) review (alongside other peptides) to evaluate safety, pharmacology and compounding quality.
Verification
The COA standard, applied
Cross-checked against PubMed-indexed primary human trials and reviews (including the explicitly skeptical 2006 'unresolved riddle' review and the 2001 safety editorial), FDA 503A bulk-substance/PCAC regulatory materials, and community/vendor sources (clearly down-weighted). Where sources conflicted (e.g., half-life 7-8 min vs 15-30 min; immunogenicity emphasis), the disagreement is flagged rather than resolved falsely. Specific PMIDs/statistics were not fabricated; citations are PubMed/ClinicalTrials search URLs.
The full verification standard →Sources
Where this comes from
- PubMed: DSIP human sleep / insomnia double-blind trials ↗· Primary small human trials from the 1980s-90s (IV dosing, mixed/weak results) that underpin the B evidence grade.
- PubMed: DSIP, a still unresolved riddle (2006 review) ↗· Skeptical review; no receptor/gene found, sleep link uncharacterized after decades.
- PubMed: DSIP review (Graf & Kastin) and pharmacology ↗· Background on structure, history, short half-life, and breadth of claimed (mostly animal) effects.
- ClinicalTrials.gov: DSIP / delta sleep-inducing peptide ↗· Use to confirm the absence of modern registered efficacy trials for sleep.
- FDA Pharmacy Compounding Advisory Committee (PCAC) materials ↗· Regulatory status: Emideltide/DSIP 503A bulk-substance review; PCAC meeting scheduled July 24, 2026; immunogenicity raised as class-level concern.
The four lenses reflect the evidence and the real-world record as of the last review and will change as data arrives. Real-world signal and reported feedback are anecdote, not proof. Nothing here is medical advice or a prescription.